Suppr超能文献

含N,N'-二取代脲部分的新型1H-吡唑衍生物作为潜在抗黑素瘤药物的修饰、生物学评价及构效关系研究

Modification, Biological Evaluation and SAR Studies of Novel 1H-Pyrazol Derivatives Containing N,N'-Disubstituted Urea Moiety as Potential Anti-melanoma Agents.

作者信息

Ruan Ban-Feng, Lin Meng-Xue, Shao Qin, Wang Tian-Hong, Zhang Qing, Dong Yu-Lu, Bu Chao-Nan, Xu Hua-Jian, Zhou Ben-Guo, Li Qing-Shan

机构信息

School of Biological and Medical Engineering, Hefei University of Technology, Hefei, 230009, P. R. China.

Tobacco Research Institute, Anhui Academy of Agricultural Sciences, Hefei, 230031, P. R. China.

出版信息

Chem Biodivers. 2018 Jun;15(6):e1700504. doi: 10.1002/cbdv.201700504. Epub 2018 May 18.

Abstract

Malignant melanomas are amongst the most aggressive cancers. BRAF Inhibitors have exhibited therapeutic effects against BRAF-mutant melanoma. In continuation of our earlier studies on anti-melanoma agents based on 1H-pyrazole skeleton, two sets of novel compounds that include 1H-pyrazole-4-amines FA1 - FA13 and corresponding urea derivatives FN1 - FN13 have been synthesized and evaluated for their BRAF inhibitory and antiproliferation activities. Compound FN10 displayed the most potent biological activity against BRAF (IC = 0.066 μm) and the A375 human melanoma cell line (GI = 0.81 μm), which was comparable to the positive control vemurafenib, and more potent than our previously reported 1H-pyrazole-3-amines and their urea derivatives. The results of SAR studies and molecular docking can guide further optimization and may help to improve potency of these pyrazole-based anti-melanoma agents.

摘要

恶性黑色素瘤是最具侵袭性的癌症之一。BRAF抑制剂已显示出对BRAF突变型黑色素瘤的治疗效果。在我们早期基于1H-吡唑骨架的抗黑色素瘤药物研究的延续中,合成了两组新型化合物,包括1H-吡唑-4-胺FA1 - FA13和相应的脲衍生物FN1 - FN13,并对其BRAF抑制和抗增殖活性进行了评估。化合物FN10对BRAF(IC = 0.066μm)和A375人黑色素瘤细胞系(GI = 0.81μm)表现出最有效的生物活性,这与阳性对照维莫非尼相当,且比我们之前报道的1H-吡唑-3-胺及其脲衍生物更有效。构效关系研究和分子对接的结果可以指导进一步优化,并可能有助于提高这些基于吡唑的抗黑色素瘤药物的效力。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验